tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Exelixis (EXEL)
NASDAQ:EXEL
US Market
EXEL
Exelixis
Overview
Analyst Forecasts
AI Stock Analysis
News & Insights
Financials
Dividends
Technical Analysis
Options
Chart
Earnings
Ownership
Historical Prices
Stock Buybacks
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Exelixis (EXEL) Stock News & Sentiment

Compare
2,914 Followers
Exelixis Launches Special Equity Award Program
Premium
Company Announcements
Exelixis Launches Special Equity Award Program
2d ago
8K
EXEL
Exelixis’s Strategic Positioning and sNDA Approval for Cabometyx Drive Buy Rating
Premium
Ratings
Exelixis’s Strategic Positioning and sNDA Approval for Cabometyx Drive Buy Rating
7d ago
EXEL
Exelixis Buy Rating: FDA Approval of Cabozantinib and Growth Catalysts Drive Positive Outlook
Premium
Ratings
Exelixis Buy Rating: FDA Approval of Cabozantinib and Growth Catalysts Drive Positive Outlook
7d ago
EXEL
Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market
Premium
Ratings
Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market
7d ago
EXEL
Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
Premium
Ratings
Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
2M ago
EXEL
Exelixis Earnings Call: Positive Growth and Ambitious Goals
Premium
Company Announcements
Exelixis Earnings Call: Positive Growth and Ambitious Goals
2M ago
EXEL
Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
Premium
Ratings
Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
2M ago
EXEL
More EXEL News >

EXEL News on the Web

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Zacks
Neutral
Guggenheim Remains a Buy on Exelixis (EXEL)
TipRanks News
Neutral
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
Zacks
Neutral
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
Zacks
Bullish
Exelixis' cabozantinib approval 'certainly positive,' says Citi
The Fly
Neutral
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Zacks
Bullish
Exelixis Inc (EXEL) to Present Promising Preclinical Data at AACR Annual Meeting 2025
GuruFocus News
Bullish
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
Zacks
Neutral

News Score - Last 7 Days

Neutral
EXEL
Sector Average
Media Buzz
This Week3 articles
Weekly Average3.25 articles
News Sentiment
This Week50%
Sector Average58%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is EXEL’s Media Buzz Sentiment?
3 articles about EXEL were published this week. In an average week, 3.25 articles are published.
    What is EXEL’s weekly average amount of articles?
    In an average week, 3.25 articles about EXEL are published.
      What is EXEL’s News Sentiment?
      50% of articles about EXEL were positive this week, compared to its sector average of 58%.
        Healthcare Stocks that are Trending in the News
        GRIGRI Bio
        CORTCorcept Therapeutics
        OGNOrganon
        INMBInmune Bio
        PIIIP3 Health Partners
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing